Proactively Reducing Anti‐Drug Antibodies via Immunomodulatory Bioconjugation

Although PEGylation reduces the immunogenicity of protein drugs to some extent, its limitations for highly immunogenic biotherapeutics have been demonstrated. Herein, a proactive strategy to alleviate the development of anti‐drug antibodies (ADAs) against protein drugs by immunomodulatory bioconjugation is reported. Rapamycin was conjugated to a PEGylated protein therapeutic via a cleavable disulfide linker. The conjugated rapamycin can be released from the bioconjugate and prevent immune responses once the bioconjugate is uptaken by antigen‐presenting cells. The immunomodulatory bioconjugate significantly reduced the titers of ADAs compared with a PEGylated protein. The inhibition of immune responses was specific to the conjugated antigen, avoiding systemic immune suppression and the risk of increased susceptibility to infections. The reported approach breaks the limitations of PEGylation by the proactive prevention of ADAs. Immunomodulatory bioconjugation: An immunomodulator rapamycin was conjugated to a PEGylated protein therapeutic via a cleavable disulfide linker. This immunomodulatory bioconjugation effectively reduces anti‐drug antibody (ADA) generation by inducing antigen‐specific immune tolerance. The reported approach breaks the limitations of PEGylation by the proactive prevention of the generation of ADAs.